Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.~* A male or female aged 61 years or above at the time of the first vaccination.~* Written informed consent obtained from the subject.~* Healthy subjects or subjects with well controlled underlying disease.~Exclusion Criteria:~* Administration of the licensed MF59-containing vaccines, e.g. Fluad™ or Addigrip™ or virosome-based influenza vaccines such as Inflexal V™, InfectoVac Flu™ or Invivac™ during the 2006-2007 influenza season.~* Administration of licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study.~* Planned administration of a vaccine not foreseen by the study protocol up to 30 days after the second vaccination with H5N1 vaccine.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first administration of the study vaccine.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).~* History of chronic alcohol consumption and/or drug abuse.~* History of hypersensitivity to vaccines.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine (including egg and thiomersal allergy).~* Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.~* Acute disease at the time of enrolment.~* Serious chronic disease including any medically significant chronic pulmonary, cardiovascular, renal, neurological, psychiatric or metabolic disorder, as determined by medical history and physical examination.~* Administration of immunoglobulins and/or any blood products within the three months preceding the first vaccination or during the study.~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to the first vaccination, or planned use during the study period.~* Any condition which, in the opinion of the investigator, prevents the subject from participation in the study.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- GSK1562902A 1 Group (Type: EXPERIMENTAL): Subjects aged 61 years or older at the time of first vaccination received 1 dose of GSK1562902A adjuvanted vaccine at Day 0. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm.
- GSK1562902A 2 Group (Type: EXPERIMENTAL): Subjects aged 61 years or older at the time of first vaccination received 1 dose of GSK1562902A non-adjuvanted vaccine at Day 0. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm.
- GSK1562902A 3 Group (Type: EXPERIMENTAL): Subjects aged 61 years or older at the time of first vaccination received 2 doses of GSK1562902A adjuvanted vaccine at Days 0 and 21. The vaccine was administered in the deltoid region of each arm.
- GSK1562902A 4 Group (Type: EXPERIMENTAL): Subjects aged 61 years or older at the time of first vaccination received 2 doses of GSK1562902A non-adjuvanted vaccine at Days 0 and 21. The vaccine was administered in the deltoid region of each arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete